Piperazine-Based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element
- 14 August 2001
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (16) , 2143-2146
- https://doi.org/10.1016/s0960-894x(01)00381-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140Journal of Virology, 2001
- HIV-1 entry – an expanding portal for drug discoveryDrug Discovery Today, 2000
- Chemokine Receptors: Keys to AIDS Pathogenesis?Cell, 1998
- Chemokine Receptors As HIV Co-Receptors: Targets for Therapeutic Intervention in AIDSPublished by Elsevier ,1998
- Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor geneNature, 1996
- Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 InfectionCell, 1996
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995
- Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear PhagocytesVirology, 1995
- A practical enantioselective synthesis of .alpha.,.alpha.-diaryl-2-pyrrolidinemethanol. Preparation and chemistry of the corresponding oxazaborolidinesThe Journal of Organic Chemistry, 1991
- Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implicationsJournal of the American Chemical Society, 1987